Cizzle Biotechnology PLC begins first day of dealings on London’s main market
The company, previously known as Bould Opportunities, is developing a blood test for the early detection of lung cancers
Cizzle Biotechnology PLC, the new name of PLC (), has begun its first day of dealings on the standard segment of the main market of the London Stock Exchange.
The company, which is developing a blood test for the early detection of lung cancers, said ahead of the listing it raised £2.2mln through the placing of 22mln new shares at a price of 10p each.
Cizzle added that it intends to use the proceeds of the fundraising to support the development of its C1Z1B biomarker test and its progress through to CE marking and/or clearance from the US Food and Drug Administration (FDA).
C1Z1B is a variant of the naturally occurring cell nuclear protein C1Z1 that is highly correlated with early-stage lung cancer.
“We are delighted to start trading on the Main Market of the London Stock Exchange today. Cizzle Biotechnology is engaged in a very exciting area of development which is seeking to address an urgent clinical need and could potentially provide significant benefits to both patients and the health care system, as well as potentially significant competitive and commercial advantages for the company. We are very excited to be embarking on the journey ahead with the support of our key stakeholders,” Cizzle executive chairman Allan Syms said in a statement.
In early trading on Friday, the company’s shares had made a good start to life as a listed firm and were changing hands at 11.5p, a 15% premium to the fundraising price.
Read More: Cizzle Biotechnology PLC begins first day of dealings on London’s main market